Invitae Hereditary Nervous System/Brain Cancer Panel
Use
The Invitae Hereditary Nervous System/Brain Cancer Panel analyzes genes associated with predisposition to brain and nervous system tumors. This broad panel testing provides efficient evaluation of several potential genes based on a single clinical indication, aiding in confirming a clinical diagnosis, predicting disease prognosis, facilitating early detection of symptoms, informing family planning and genetic counseling, and promoting enrollment in clinical trials. It is not designed for the detection of somatic mutations in tumor tissue.
Special Instructions
Genetic testing of these genes may help in confirming a clinical diagnosis, facilitating early detection of symptoms, informing family planning, or promoting enrollment in trials. The test focuses on heritable germline mutations.
Limitations
The test is designed for heritable germline mutations and is not suitable for detecting somatic mutations in tumor tissue. Some genes analyzed might be linked to disorders not listed here. Analysis covers coding exons and select non-coding variations. Some variants, like structural rearrangements, may not be detected. Some regions and types of variants may not be fully covered. In rare cases, blood or DNA samples might not accurately represent the patient's genome due to factors like recent transplants or transfusions. Specific limitations are detailed in the provided report.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)